deepeye® TPS is in the final phase of obtaining regulatory approval (CE). Stay tuned !
and patients with neovascular age-related macular degeneration (nAMD)
* CE marking pending. deepeye® TPS is a medical device that may present potential risks as a treatment planning aid for patients with nAMD. For comprehensive safety information, please consult the electronic instructions for use.
Providing a second OCT reading anytime & everywhere, advancing care from reactive “treat & extend” to proactive “predict & treat”.
Pays for itself within months by increasing reimbursement potential (depending on country).
One-click workflow safes expert-time in patient education & OCT documentation.
Works with OCT imaging software like HEYEX2 and most major OCT devices.
By doctors for doctors. Here is what the first users of deepeye say.
"For the first time, the deepeye solution enables a needs-oriented, patient-specific treatment strategy."
"I don’t need AI to recognize AMD.
I need deepeye to predict my patients’ disease progression."
”The first deepeye analyses of DME make me confident that, after AMD patients, we can also use this great tool for diabetics.”
AI-based medical device software
(clinical decision support system | CDSS)
Anytime & everywhere with 1 click
90+% real-world data from ~200 leading ophthalmic centers, that achieved exceptional therapy outcomes.
Complaint with all 5 principles for ethical AI by German Ophthalmology Association (DOG) and Professional Association of Ophthalmologists in Germany (BVA).
AI processes only de-identified OCTs via a secure connection and deletes the scan after analysis (relative anonymization in line with GDPR).
.gif)
Based on tens of thousands of similar cases, treated with exceptional results.
Assessment of current disease activity, explained by biomarker visualization.
Prediction of expected treatment need over the coming 12 months.
Works with most OCT machines and imaging software like HEYEX2.
